FDA Puts Idenix Hep C Drug On Hold Amid Bristol-Myers Woes
Idenix Pharmaceuticals Inc. on Monday said the U.S. Food and Drug Administration has temporarily blocked patients from using an experimental hepatitis C drug after the death of a clinical trial participant...To view the full article, register now.
Already a subscriber? Click here to view full article